{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:14:31Z","timestamp":1788196471728,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["EORTC 18071"],"award-info":[{"award-number":["EORTC 18071"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejca.2021.08.028","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T21:51:34Z","timestamp":1634334694000},"page":"225-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma"],"prefix":"10.1016","volume":"158","author":[{"given":"Jeffrey S.","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-1685","authenticated-orcid":false,"given":"Mark R.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Hennicken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-0973","authenticated-orcid":false,"given":"Roberto","family":"Zoffoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adenike","family":"Amadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Kupas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srividya","family":"Kotapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-7103","authenticated-orcid":false,"given":"Andriy","family":"Moshyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2021.08.028_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11912-017-0594-5","article-title":"Adjuvant therapy for melanoma","volume":"19","author":"Agha","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"33","key":"10.1016\/j.ejca.2021.08.028_bib2","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy for melanoma: ASCO guideline","volume":"38","author":"Seth","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.08.028_bib3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2021.08.028_bib4","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2021.08.028_bib5","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2021.08.028_bib6","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2021.08.028_bib7","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2021.08.028_bib8","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.08.028_bib9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2021.08.028_bib10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2020.03.011","article-title":"Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma","volume":"132","author":"Hemstock","year":"2020","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.ejca.2021.08.028_bib11","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.08.028_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2020.07.011","article-title":"Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors","volume":"137","author":"Coart","year":"2020","journal-title":"Eur J Cancer"},{"issue":"suppl 15","key":"10.1016\/j.ejca.2021.08.028_bib13","article-title":"Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma","volume":"39","author":"Grossmann","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.08.028_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2021.08.028_bib15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.ejca.2021.08.028_bib16","first-page":"S1142","article-title":"Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG\/Keynote 054 double-blinded phase III trial","volume":"31","author":"Eggermont","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.08.028_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12885-020-07538-1","article-title":"Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis","volume":"21","author":"Toor","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2021.08.028_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/21556660.2019.1649266","article-title":"An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma","volume":"8","author":"Lorenzi","year":"2019","journal-title":"J Drug Assess"},{"issue":"36","key":"10.1016\/j.ejca.2021.08.028_bib19","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921005554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921005554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:31:50Z","timestamp":1777599110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921005554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":19,"alternative-id":["S0959804921005554"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.08.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}